• Rhelion signed a licensing agreement to supply Filament Health’s PEX010 psilocybin drug candidate to the University of Washington.
• PEX010 shipment supports an investigator-initiated Phase 2a trial in cancer-related anxiety and depression using a group retreat therapy model.
• Trial registered as NCT07336238; sponsor and principal investigator is University of Washington’s Dr. Anthony Back.
• Filament supplies the investigational drug product; it is not the trial sponsor and will not run the study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608250720NEWSFILECNPR____20260825_311389_1) on August 25, 2026, and is solely responsible for the information contained therein.